Skip to main content
. 2009 Nov;11(6):508–513. doi: 10.2353/jmoldx.2009.090022

Figure 2.

Figure 2

Identification of KRAS mutations by RH. Test trips obtained after hybridization and enzymatic color development are shown. Strips 1–10: Mutant-enriched PCR was perfomed using a mix of 50 ng wild-type and 0.5 ng genomic DNA derived from tumor cell lines (strips 1, 2, 4, 5, 7–10) and mutant PCR product generated by site-directed mutagenesis (strips 3, 6), respectively. Strips 11–18: Mutant-enriched PCR was performed on genomic DNA isolated from selected FFPE tissue samples (strips 11–16). The following genotypes were identified: Val12 (strip 11), Cys12/Cys13 (strip 12), Asp13 (strip 13), Asp12 (strip 14), Cys12 (strip 15), Ala12 (strip 16), 50 ng Colo320 (strip 17), and negative PCR control (strip 18).